Lixisenatide (Adlyxin) approved to treat type 2 diabetes

August 01, 2016 – Type 2 diabetes affects more than 29 million people and accounts for more than 90 percent of diabetes cases diagnosed in the United States. Over time, high blood sugar levels can increase the risk for serious complications, including heart disease, blindness and nerve and kidney damage.

Lixisenatide (Adlyxin)

Lixisenatide (Adlyxin)

In an effort widen the therapy options for the treatment of the condition, on July 28, 2016, the American Food & Drug Administration (FDA) approved Lixisenatide (Adlyxin), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

Lixisenatide (Adlyxin) is a glucagon-like peptide-1 (GLP-1) receptor agonist, a hormone that helps normalize blood sugar levels. The drug’s safety and effectiveness were evaluated in 10 clinical trials that enrolled 5,400 patients with type 2 diabetes. In these trials, Lixisenatide (Adlyxin) was evaluated both as a standalone therapy and in combination with other FDA-approved diabetic medications, including metformin, sulfonylureas, pioglitazone and basal insulin. Use of Lixisenatide (Adlyxin) improved hemoglobin A1c levels (a measure of blood sugar levels) in these trials. Moreover, more than 6,000 patients with type 2 diabetes at risk for atherosclerotic cardiovascular disease were treated with either Lixisenatide (Adlyxin) or a placebo in a cardiovascular outcomes trial. Use of Lixisenatide (Adlyxin) did not increase the risk of cardiovascular adverse events in these patients.

The most common side effects associated with Lixisenatide (Adlyxin) are nausea, vomiting, headache, diarrhea and dizziness. Hypoglycemia in patients treated with both Lixisenatide (Adlyxin) and other antidiabetic drugs such as sulfonylurea and/or basal insulin is another common side effect. In addition, severe hypersensitivity reactions, including anaphylaxis, were reported in clinical trials of Lixisenatide (Adlyxin). Also, Lixisenatide (Adlyxin) should not be used to treat people with type 1 diabetes or patients with increased ketones in their blood or urine (diabetic ketoacidosis).

The FDA is still requiring two types of post-marketing studies for Lixisenatide (Adlyxin), namely a) clinical studies to evaluate dosing, efficacy and safety in paediatric patients, and b) a study evaluating the immunogenicity of Lixisenatide (Adlyxin).

Previously, Lixisenatide had been approved by the European Medicines Agency in 2013 under the trade name Lyxumia. Additional information on diabetes can be found under  FDA: Diabetes Information.

thassodotcom

Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Posted in New Drug Approval, Thasso Post, Theragenomic Medicine
Tags: , , , , ,

Leave a Reply

Optional: Social Subscribe/Login



Your email address will not be published. Required fields are marked *

*

thasso post magazine

View my Flipboard Magazine.

follow thasso

Facebooktwittergoogle_pluslinkedinrssyoutubeby feather

subscribe to thasso

By signing up, you agree to our Terms of Service and Privacy Policy.

calendar

April 2017
M T W T F S S
« Mar    
 12
3456789
10111213141516
17181920212223
24252627282930

categories

archive

tweets